Unknown

Dataset Information

0

Engagement of monocytes, NK cells, and CD4+ Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIVmac251 vaginal acquisition.


ABSTRACT: The recombinant Canarypox ALVAC-HIV/gp120/alum vaccine regimen was the first to significantly decrease the risk of HIV acquisition in humans, with equal effectiveness in both males and females. Similarly, an equivalent SIV-based ALVAC vaccine regimen decreased the risk of virus acquisition in Indian rhesus macaques of both sexes following intrarectal exposure to low doses of SIVmac251. Here, we demonstrate that the ALVAC-SIV/gp120/alum vaccine is also efficacious in female Chinese rhesus macaques following intravaginal exposure to low doses of SIVmac251 and we confirm that CD14+ classical monocytes are a strong correlate of decreased risk of virus acquisition. Furthermore, we demonstrate that the frequency of CD14+ cells and/or their gene expression correlates with blood Type 1 CD4+ T helper cells, ?4?7+ plasmablasts, and vaginal cytocidal NKG2A+ cells. To better understand the correlate of protection, we contrasted the ALVAC-SIV vaccine with a NYVAC-based SIV/gp120 regimen that used the identical immunogen. We found that NYVAC-SIV induced higher immune activation via CD4+Ki67+CD38+ and CD4+Ki67+?4?7+ T cells, higher SIV envelope-specific IFN-? producing cells, equivalent ADCC, and did not decrease the risk of SIVmac251 acquisition. Using the systems biology approach, we demonstrate that specific expression profiles of plasmablasts, NKG2A+ cells, and monocytes elicited by the ALVAC-based regimen correlated with decreased risk of virus acquisition.

SUBMITTER: Gorini G 

PROVIDER: S-EPMC7093029 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Engagement of monocytes, NK cells, and CD4+ Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIVmac251 vaginal acquisition.

Gorini Giacomo G   Fourati Slim S   Vaccari Monica M   Rahman Mohammad Arif MA   Gordon Shari N SN   Brown Dallas R DR   Law Lynn L   Chang Jean J   Green Richard R   Barrenäs Fredrik F   Liyanage Namal P M NPM   Doster Melvin N MN   Schifanella Luca L   Bissa Massimiliano M   Silva de Castro Isabela I   Washington-Parks Robyn R   Galli Veronica V   Fuller Deborah H DH   Santra Sampa S   Agy Michael M   Pal Ranajit R   Palermo Robert E RE   Tomaras Georgia D GD   Shen Xiaoying X   LaBranche Celia C CC   Montefiori David C DC   Venzon David J DJ   Trinh Hung V HV   Rao Mangala M   Gale Michael M   Sekaly Rafick P RP   Franchini Genoveffa G  

PLoS pathogens 20200312 3


The recombinant Canarypox ALVAC-HIV/gp120/alum vaccine regimen was the first to significantly decrease the risk of HIV acquisition in humans, with equal effectiveness in both males and females. Similarly, an equivalent SIV-based ALVAC vaccine regimen decreased the risk of virus acquisition in Indian rhesus macaques of both sexes following intrarectal exposure to low doses of SIVmac251. Here, we demonstrate that the ALVAC-SIV/gp120/alum vaccine is also efficacious in female Chinese rhesus macaque  ...[more]

Similar Datasets

| S-EPMC5026031 | biostudies-literature
| S-EPMC4534401 | biostudies-literature
| S-EPMC3121878 | biostudies-other
| S-EPMC4767727 | biostudies-literature
| S-EPMC4335709 | biostudies-literature
| S-EPMC7685735 | biostudies-literature
| S-EPMC5997355 | biostudies-literature
| S-EPMC4841252 | biostudies-literature
| S-EPMC5916782 | biostudies-literature
| S-EPMC3608750 | biostudies-literature